Nordic Bioscience’s Post

📢📄 [#PressRelease] May 30, 2024: Lys Therapeutics Announces Significant Scientific Advances in Neurodegenerative and Neurovascular Diseases With several #publications and oral #presentations at international medical conferences, Lys Therapeutics consolidates its scientific advances and demonstrates the quality of its research in the fields of #Stroke, #Parkinson's disease, and #MultipleSclerosis.   Lyon & Caen, France, May 30, 2024 – Lys Therapeutics, a pioneering French biotechnology company revolutionizing the treatment of patients with neurodegenerative and neurovascular diseases, today announces a series of scientific advances made public during the first half of 2024. These include six events (plenary presentations, oral communications, publications, and posters) where Lys Therapeutics presented major preclinical results in its two strategic areas: emergency medicine (including strokes) and neurodegenerative diseases (such as Parkinson's disease and multiple sclerosis). More information on https://lnkd.in/gwWwQ2rR

There are so many rodent models available for preclinical target and drug discovery for #MASH. But which model offers the highest resemblance of the human disease?   The answer is simple. In the recent issue of Nature Metabolism, the renowned #LITMUS consortium concludes that Gubra’s GAN DIO-MASH mouse model ranks #1 for human proximity, a key indicator of clinical translatability, in terms of both metabolic relevance and ability to induce MASH-fibrosis. LITMUS compared a wide range of the most commonly used preclinical MASH models, evaluating their metabolic phenotype, liver histopathology and transcriptomics against corresponding MASH patient data.    We are very proud and grateful to be recognized by LITMUS as the provider of the most translational preclinical model.   Check out the paper and explore the objective ranking of preclinical models of MASH in the industry. #PreclinicalModel #PreclincalResearch #ClinicalTranslatability #MASLD #Publication #PreclinicalCRO #ResearchModels

Proud to share Selda’s new article on ruthenium-based photoactivated chemotherapy in ACS Journal of Medicinal Chemistry! Selda studied the interaction between the two photoproducts released upon light irradiation of a PACT compound: the photocage, and the anticancer drug. She realised her study a glioblastoma in vitro tumour model, where our target NAMPT protein is over-expressed. Strikingly, she found first that the ruthenium photocage is not necessarily as biologically inert as what is often believed, and second that the two photoproducts produced by light activation do interact biologically speaking. Importantly, this interaction depends on the oxygenation levels: In normoxia she found concentration-dependent interactions, while under hypoxia she found clear synergism. She also introduces an important distinction between on the one hand, the observation that two fragments may interact synergistically, and on the other hand, a high value of the photoindex. Well done Selda! and thanks to all co-authors who have contributed on this paper, and in particular Yurii who made large and pure batches of the compound so that the biologists can work with it ! Also thanks to Sylvia Le Dévédec from LACDR for this fruitful, long standing, collaboration. #leidenscience

Frontage and Telomir Pharmaceuticals recently presented promising pre-clinical data for Telomir‘s lead development product at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024. The data highlighted the effect of Telomir-1 on telomere length in three human cell lines: MRC-5 fetal lung fibroblasts, human umbilical endothelial cells (HUVEC), and mesenchymal stem cells (MSC). Senior Scientist, Danielle Piazza Baker, PhD, of Frontage, presented the poster, titled “Telomir-1 Induces Telomere Extensions in Primary Human Cell Strains,” at the conference, which took place earlier this year. The data presented further demonstrated how Telomir-1 increases telomere length and its potential to successfully affect age-related inflammatory conditions. 👉 Learn more about this exciting news here: https://ow.ly/QcEj50R5IPL #drugdevelopment #preclinical #cro

𝗔𝗿𝗲 𝘆𝗼𝘂 𝘄𝗼𝗿𝗸𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗰𝗮𝗿𝗱𝗶𝗮𝗰 𝗺𝗼𝗱𝗲𝗹𝘀 𝗳𝗼𝗿 𝗽𝗿𝗲-𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝘀𝘀𝗮𝘆𝘀? 𝗗𝗼𝗻’𝘁 𝗺𝗶𝘀𝘀 𝘁𝗵𝗲 𝘀𝗲𝗰𝗼𝗻𝗱 𝗲𝗱𝗶𝘁𝗶𝗼𝗻 𝗼𝗳 𝗟𝗮𝗯𝗜𝗡𝗔𝗥 𝗕𝗥𝗘𝗔𝗞 Join Dr. Ravi Vaidyanathan from FUJIFILM Cellular Dynamics, Inc for an enlightening webinar hosted by innoVitro. The webinar will explore how 2D and 3D co-culture systems enhance the relevance of these cell models, bridging the gap between lab research and clinical success. Here’s why you should attend: 🌱 Introduction to iCell cardiac fibroblasts: These high-purity cells exhibit low lot-to-lot variability and express specific markers like POSTN, TE7, and Cx43. 🧪 Enhanced co-culture models: Learn about co-culturing iCell Cardiomyocytes² with iCell Cardiac Fibroblasts and/or endothelial cells in 2D and 3D systems, providing advanced models for preclinical screening assays. If you're a researcher in cardiac physiology, drug discovery, or regenerative medicine, this webinar is for you. Make sure to save your spot! 🔗 Register here: https://lnkd.in/dht5JBxB #Cardiac #Fibroblasts #DrugDevelopment #PreclinicalResearch #HumanCellModels #Pharmaceuticals #Cardiomyocytes

Are you looking to tap into a unique genetic heritage and high-quality data to accelerate your research? Find research subjects faster, discover novel targets and biomarkers, and investigate with a multi-omic perspective. If so, then join this 30 September webinar for a dive into biomedical research with the Finnish biobanks. Click below to see the agenda and to register. #biobank #finbb #genomics #pharma #biomedical #research

LabX Media Group Technology Editor Damon Anderson, PhD, spoke to Shan D., our VP of Strategy and Innovation, recently about Molecular Devices’ latest collaboration with Danaher Corporation and Cincinnati Children's aimed at improving liver organoid technology as a drug toxicity screening solution: https://ow.ly/EkI550QFXjg. While liver organoids predict drug-induced liver injury in the preclinical phase with roughly 80 percent accuracy – this compares to just 33 to 50 percent accuracy of today’s more widely used in-vitro models. In Q&A-fashion, the two explore what’s holding organoid adoption back and the promise these advanced screening platforms offer for future drug development and disease research. Read it all, here: https://ow.ly/EkI550QFXjg. #scienceandtechnology #3dbiology #organoids #AI #labautomation #cellculture #drugdiscovery #drugdevelopment #diseaseresearch #DILI #IntheNews

🎉 Exciting News from Sino Biological, Inc.! 🎉 We're thrilled to announce the release of our latest innovations in biotechnology and life sciences. Our commitment to advancing research and applications in the field has led us to develop a range of groundbreaking products. Here's what's new: 🔹 GMP Grade Products - Elevating the standards of research and therapeutic applications, we're introducing additional Animal-Free Human GMP grade products, including: 🔸Flt3 Ligand protein 🔸IL21 🔸SCF (Stem Cell Factor) These high-quality products are designed to meet the most rigorous requirementd, ensuring safety, efficacy, and regulatory compliance. 🔹 Full-Length Human A2aR (Adenosine A2a Receptor) - A pivotal addition to our catalog, offering immense potential for research in neurology, cardiology, and immunology. 🔹 Human CLEC17A Protein - This novel offering opens new avenues for research in hematopoiesis, immune response, and cancer biology. 🔹 Cytokines - Expanding our portfolio with a variety of cytokines to support research in cellular communication, immune system regulation, and inflammation. These products stand at the forefront of innovation, offering unparalleled quality, activity and specificity. Designed to accelerate research and development in biopharmaceuticals, immunology, cell biology, and more, they represent our ongoing commitment to supporting scientists and researchers worldwide. Let's drive the future of science together! Get your samples today! #SinoBiological #Biotechnology #LifeSciences #Innovation

Delve into the forefront of targeted protein degradation (TPD) with an exploration of PROTACs and Molecular Glue Degraders (MGDs) from a drug discovery perspective. Authored by Sygnature Discovery members, Dr Roland Hjerpe (corresponding author), Dr Allan Jordan, Ms Rachel L., Dr Francesca Cavallo, alongside Mr Corentin BOUVIER, Dr Wendy Xolalpa, and Dr Manuel S. Rodriguez, this TPD review delves into: 🔵 Mechanistic concepts and discovery approaches for PROTACs and MGDs 🔵 Current clinical and pre-clinical status of targeted protein degradation in oncology, neurodegenerative, and inflammatory diseases. Read the full review here: https://lnkd.in/gqZBDTQH #targetedproteindegradation #PROTAC #molecularglues #drugdiscovery

🚀 Exciting news! A new study from the Università degli Studi di Trieste explores the potential of microRNA (miRNA) profiles in neuron-derived extracellular vesicles (NDEVs) as predictive biomarkers for adverse drug reactions (ADRs) in children receiving ketamine. 🔬 This research, leveraging TAmiRNA GmbH's Next-Generation Sequencing (NGS)-based #miND® pipeline, identified specific miRNAs (miR-18a-3p, miR-484, and miR-548az-5p) as potential tools to predict ketamine-induced ADRs. 💡 This breakthrough not only advances our understanding of ketamine's side effects in children but also demonstrates the biomarker potential of organ-specific #EVs and their miRNA cargo. Read the full study: https://lnkd.in/d2QKBTND #miRNA #EVs #TAmiRNA #biomarkers #NGS #ClinicalPharmacology #TranslationalScience #PediatricMedicine